scispace - formally typeset
S

Somnuek Sungkanuparph

Researcher at Mahidol University

Publications -  262
Citations -  7063

Somnuek Sungkanuparph is an academic researcher from Mahidol University. The author has contributed to research in topics: Efavirenz & Nevirapine. The author has an hindex of 42, co-authored 247 publications receiving 6424 citations. Previous affiliations of Somnuek Sungkanuparph include Thailand Ministry of Public Health & Washington University in St. Louis.

Papers
More filters
Journal ArticleDOI

Saliva sample as a non-invasive specimen for the diagnosis of coronavirus disease 2019: a cross-sectional study.

TL;DR: Saliva might be an alternative specimen for the diagnosis of COVID-19 if the collection is non-invasive, and non-aerosol generating, given the simplicity of specimen collection and good diagnostic performance.
Journal ArticleDOI

Survival rate and risk factors of mortality among HIV/tuberculosis-coinfected patients with and without antiretroviral therapy.

TL;DR: Antiretroviral therapy substantially reduces mortality rate among HIV/TB-coinfected patients and Initiation of ART within 6 months of TB diagnosis is associated with greater survival.
Journal ArticleDOI

Geographic and temporal trends in the molecular epidemiology and genetic mechanisms of transmitted HIV-1 drug resistance: an individual-patient- and sequence-level meta-analysis

Soo-Yon Rhee, +72 more
- 07 Apr 2015 - 
TL;DR: Most TDR strains in SSA and SSEA arose independently, suggesting that ARV regimens with a high genetic barrier to resistance combined with improved patient adherence may mitigate TDR increases by reducing the generation of new ARV-resistant strains.
Journal ArticleDOI

Options for a second-line antiretroviral regimen for HIV type 1-infected patients whose initial regimen of a fixed-dose combination of stavudine, lamivudine, and nevirapine fails.

TL;DR: Almost all patients who experienced treatment failure with their first antiretroviral regimen, a fixed-dose combination of stavudine, lamivUDine, and nevirapine, have lamivudine and nonnucleoside reverse-transcriptase inhibitor resistance.